Prenatal screening is offered to pregnant women because all pregnancies have a small chance for a genetic disorder, regardless of maternal age, family history, or personal health. Screening is traditionally done through routine tests such as analyzing maternal blood and/or performing an ultrasound.

New blood tests called noninvasive prenatal tests (NIPT) have been developed to analyze the DNA of your baby. These tests are much more accurate than other standard screening tests currently available. However, an invasive test, in which a sample from the placenta (chorionic villus sampling) or the amniotic fluid (amniocentesis) is taken for testing, is still necessary to confirm diagnosis following a positive NIPT result.



If you have any further questions on noninvasive prenatal testing, please ask your healthcare provider.

References

- McCullough et al. Non-Invasive Prenatal Chromosomal Aneuploidy Testing -Clinical Experience: 100,000 Clinical Samples. (2014) PLoS ONE 9 (10): e109173.
- Gregg et al. Non-invasive prenatal screening for fetal aneuploidy: 2016 update. Genet Med. (2016) doi:10.1038/gim.2016.97
- Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–237

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Sex determination is not offered in India under PNDT regulation.

PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country-specific recommendations, consult your local health care professional.

Vanadis is a registered trademark of PerkinElmer.

PerkinElmer, Inc. 940 Winter Street Waltham, MA 02451 USA P: (800) 762-4000 or (+1) 203-925-4602 www.perkinelmer.com



For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright ©2018-2019 PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.

013809A 03





What is the Vanadis NIPT test?

Vanadis is the next-generation noninvasive prenatal test developed to help pregnant women assess the risk of their fetus carrying a trisomy. Thanks to a technological breakthrough, the Vanadis test helps provide accurate results faster and has obtained the CE-IVD marking as a result of its proven high performance.

How does the Vanadis NIPT test work?

We now know that fragments of your baby's DNA, originating from your placenta, circulate in your blood during pregnancy. DNA is the substance that our chromosomes are made of, and it contains our genetic information. By analyzing the baby's DNA found in your blood, the Vanadis test is able to quantify the risk that your baby is affected by chromosomal conditions such as Down syndrome (trisomy 21).

How is the Vanadis NIPT test performed?

The Vanadis test can be performed from a simple blood sample and poses no risk of miscarriage to your pregnancy. About 10 mL (roughly one tablespoon) is taken from your arm like a normal blood test and sent to the laboratory for testing.

Who could benefit from Vanadis NIPT?


Any pregnant woman who wants to know whether there is a risk her baby carries a chromosomal condition such as Down syndrome can be screened using the Vanadis test. You should receive pretest counseling before testing.

When can the Vanadis NIPT test be performed?

The Vanadis test can be conducted after 10 weeks of pregnancy to ensure that there is enough of baby's DNA present in your blood to conduct the analysis.

What conditions can Vanadis NIPT identify?

Vanadis routinely screens for conditions such as Down (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes. Screening for fetal sex may also be included (if allowed by country specific legislation). The accuracy of NIPT for screening other chromosomal conditions still needs to be demonstrated and is currently not recommended by international scientific societies.²



How long does it take to get my results?

Results are typically available within one week. You can ask your obstetric provider or genetic counselor how and when you will be receiving your results.

HOW DO I INTERPRET MY RESULTS?

NIPT has demonstrated a much higher accuracy than standard screening tests for identifying trisomies 21, 18, and 13.3

Low risk result

indicates that your baby is unlikely to be affected by any of the aforementioned conditions. As an example, a T21 risk of 1:8541 indicates that there is one chance in 8,541 that your baby has Down syndrome.

Increased risk result

indicates an increased chance your baby has a specific genetic condition. As there is also a small chance that the test will incorrectly show that the baby is affected, your medical professional may discuss further diagnostic tests (such as amniocentesis or chorionic villus sampling) to confirm the presence of a chromosomal condition.

Sometimes a result cannot be obtained for a variety of reasons. In these cases, we encourage you to have a discussion with your genetic counselor or obstetric provider.